Catabasis Pharmaceuticals, a Cambridge, Mass.-based clinically staged company dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases, has raised further $8m in Series A financing.
Backers include current investors SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.
This round brings the total amount raised by the company to date to $47.6m (read here).
Founded in 2008 and led by CEO Jill C. Milne, Ph.D., Catabasis leverages the therapeutic potential of omega-3 fatty acids for the treatment of inflammatory and metabolic diseases.
The company intends to use the funding to accelerate the development of CAT-2003, its omega-3 conjugated compound for patients with severe hypertriglyceridemia, and move the compound into the clinic in 2012.